Speaker Profile

Head of Oncology Marketing, Labcorp

Biography
Ms. Rougier-Chapman is a strategic leader with deep domain expertise spanning the diagnostics, genomics and life science sectors. Over the past two decades, she has been delivering successful business growth for large multinational and rapidly scaling companies through commercialization of genomic solutions for clinical and research use. As Head of Labcorp Oncology Marketing, she is responsible for expanding the Labcorp brand and revenues by leading go-to-market efforts including growth strategy, product marketing, thought leadership and marketing programs spanning oncology drug development and diagnostics. She recently joined Labcorp through the acquisition of PGDx where she was SVP, Head of Marketing & Commercial Strategy. Ms. Rougier-Chapman also held sales & marketing leadership roles at Invitae, ArcherDx, Bionano Genomics, Agilent Technologies, as well as various commercial roles at Advanced Cell Diagnostics, Cogenics, Incyte Genomics, and Stratagene. She holds an M.S. in Molecular Cancer Biology and a B.S. in Biology from Duke University.


Clinical Dx Showcase:
PGDx

Personal Genome Diagnostics is empowering the fight against cancer by unlocking actionable information from the genome. We have developed an innovative and comprehensive portfolio of RUO and IVD tissue-based and non-invasive liquid biopsy genomic profiling solutions for use in laboratories worldwide.

LBx: Expanding Access to Precision Medicine with Innovations in Drug Dev. & Dx
Partner with PGDx from biomarker discovery to diagnosis and unlock the power of genomic data

 Session Abstract – PMWC 2022 Silicon Valley


  • Dismantling Barriers to Biomarker Testing Through Collaboration (PANEL)
    Session Chair: Omar Perez, AstraZeneca
    - Nikki Martin, LUNGevity
    - Laura J. van ’t Veer, UCSF
    - Jenn Higgins, Guardant Health
    - Kat Kwiatkowski, Strata Oncology
  • Health Systems Perspective: Leveraging Real-world Evidence to Improve Patient Care (PANEL)
    Session Chair: Anna Berry, Syapse
    - Mary Walters, Aurora Health
    - Haythem Y Ali, Henry Ford Health System
  • Comprehensive Profiling: Combination of Tissue and Plasma Biomarker Strategies
    Session Chair: Maggie Rougier-Chapman, Personal Genome Diagnostics (PGDx)
    - Cynthia Pointer, Genapsys
    - Ravi Kolhe, Augusta University
    - Stephen Miller, Blueprint Medicines
  • Immuno-oncology Biomarkers for Predicting Drug Efficacy
    Session Chair: Ronnie Andrews, Oncocyte
    - Paul Billings, Biological Dynamics
    - Kat Kwiatkowski, Strata Oncology
  • Reimagining Oncology - Closing the Gaps between Science and Clinic (PANEL)
    Session Chair: Christian Wolfrum, Siemens Healthineers
    - Ben Gonzales, Biognosys AG
    - Debanti Sengupta, Varian
    - Rangarajan Sampath, Siemens Healthineers
    - Isma Benattia, Amgen
  • Challenges to Implementing Precision Medicine in the Community Setting (PANEL)
    Session Chair: Jerry Mitchell, Foundation Medicine
    - Erika Brown, One Cancer Place
    - Vivian Lee, Patient Advocate
    - Kevin B. Knopf, Alameda Health System
    - Christopher Woods, Sutter Health
  • Single Molecule Methylation Profiling of Circulating Tumor DNA
    - Hanlee P. Ji, Stanford
  • Combined Utilization of Precision Medicine Technologies in Primary Clinics
    - Gad Rennert, Carmel Medical Center
  • PMWC Showcase
    - Paul Dempsey, Hawkeye Bio, Inc.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative